São Paulo, March 5, 2026 – Eurofarma officially launches the 2026 edition of its Sustainability Booklet — a publication that presents, through figures and concrete initiatives, the company’s commitment to responsible growth and the generation of positive impact. 

In this edition, the company highlights the main advances in its sustainability agenda, a pioneering initiative in the pharmaceutical sector, and details the investment of R$ 156.6 million made last year, allocated to Environment (R$ 41.8 million), Humanitarian Aid (R$ 34.7 million), Sports (R$ 30.7 million), Education (R$ 29.5 million), and Social Initiatives (R$ 19.9 million). 

“At Eurofarma, we treat ESG as a strategic guideline that supports our long-term growth. This means putting people at the center, operating with transparency, strengthening governance, and continuously advancing in eco-efficiency and climate commitment, guided by our materiality matrix and Vision 2027. By integrating these fronts into our business, we expand our positive impact, stimulate innovation, and reinforce our role as a reference in the pharmaceutical sector in Latin America,” says Maria Del Pilar Muñoz, Vice President of Sustainability and New Business at Eurofarma. 

Within the environmental agenda, one of the company’s pioneering fronts in the pharmaceutical sector, Eurofarma achieved 97% renewable energy in its global operations, in addition to a 62% reduction in Scope 2 emissions, the achievement of the international ISO 46001 certification (Water Efficiency Management System), among other results. 

Another highlight is its social impact, marked by the expansion of initiatives across Latin America, including the donation of more than 838,000 units of medicines and thousands of beneficiaries in programs such as the Ophthalmology Task Force, which provided eye exams to more than 5,000 students and donated glasses to 1,000 of them. In support of the Brazilian healthtech Protecting Brains & Saving Futures (PBSF), the company also contributed to monitoring newborns in six different hospitals, totaling more than 34,700 hours of neuromonitoring in neonatal ICUs. 

In education, through Instituto Eurofarma, the company reached more than 23,000 students and recorded an investment of R$ 29.5 million through the institute in the last year. The company also graduated the first class from the Eurofarma Nursing Center in Montes Claros (35 graduates). Additionally, through Lactare, Eurofarma was responsible for collecting more than 4,000 liters of human milk and supporting more than 1,500 premature babies. 

In sports, the annual investment was highlighted by the launch of Team Eurofarma, which brings together athletes from different disciplines in a multi-sport project focused on the cycle leading up to the Los Angeles 2028 Games. In addition, this investment resulted in driver and team titles in Stock Car racing, reinforcing the company’s leading role in motorsports. 

With 12,000 employees, Eurofarma maintains a strategic focus on valuing people and expanding access to health and well-being, reflected in an 89% pride-of-belonging index among its employees. 
The complete material is available for reading at Sustainability Booklet - Eurofarma To follow all Eurofarma’s ESG initiatives and updates, visit the company’s social media profiles on Instagram and LinkedIn. 
 
About Eurofarma 

Founded in 1972, Eurofarma operates in the healthcare sector producing and commercializing products and services aimed at improving people’s quality of life. Focused on generating shared value, the company covers the main pharmaceutical segments such as prescription medicines, generics, hospital products, oncology, OTC medicines, personal care, and animal health, in addition to providing contract manufacturing services. With a broad coverage of therapeutic classes, its portfolio includes more than 4,000 SKUs, serving virtually all medical specialties. A leader in prescription medicines in Brazil, where it also holds the second position in generics, Eurofarma operates in 24 countries, with 100% coverage in Latin America and leadership in the region’s retail market. The company also maintains operations in the United States and Africa and employs more than 12,000 people across 11 manufacturing plants, producing 630 million units in 2025. In the same year, the company invested more than R$ 800 million in innovation projects and achieved net revenue exceeding R$ 12 billion.